Abstract Announcements

Abstract Announcements and Exceptions 

Confidentiality Policy Exceptions
According to ASCO's Confidentiality Policy, each abstract submitted to the Annual Meeting is confidential from the time of submission until the date and time when ASCO makes the abstract publicly available. Under rare, extenuating circumstances requiring a formal application, abstracts may receive an Exception to ASCO’s Confidentiality Policy.  These formal Exceptions require approval by ASCO prior to the information being made public.

The following abstracts have received formal Exceptions to ASCO’s Confidentiality Policy for the 2015 ASCO Annual Meeting:

Abstract 1001
"Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician’s Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study."

Abstract 1070
"Masitinib plus carboplatin and gemcitabine for treatment of patients with advanced triple negative breast cancer: An open label phase Ib/II trial."

Abstract 3021
"Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1."

Abstract 3073
"A first-in-human phase 1 dose-escalating trial of G305 in patients with solid tumors expressing NY‑ESO‑1."

Abstract 3083
"Pilot study of intratumoral G100, toll-like receptor-4 (TLR4) agonist, therapy in patients with Merkel cell carcinoma (MCC)."

Abstract 3502
"SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC)."

Abstract 4027
"Masitinib Plus Irinotecan for Second Line Treatment of Esophagogastric Adenocarcinoma: An Open Label Phase 1b/2 Trial."

Abstract 4543
"HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev)."

Abstract 8009
"A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC)."

Abstract 8059
"ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC)  previously treated with chemotherapy and crizotinib (CRZ)."

Abstract 8509
"Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR."

Abstract LBA7005
"Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study."

Abstract LBA8502
"GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma."

Abstract LBA10502
"Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI)."

Abstract e17637
"Patient presentation, quality of care, and overall survival in colorectal cancer: Results from the New Zealand PIPER Cohort Study."